ReviewFrontiers in molecular biosciences2026
Recent advances in m6A RNA modification in hepatocellular carcinoma: from mechanisms to therapeutic potential.
Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting.Functional & integrative genomics · 2026Review
- RNA duplex formation and competing endogenous RNA, proposed as mechanisms in regulating expression of natural antisense transcripts- from hypotheses to potential therapeutic applications.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains a major global health burden due to its high incidence and mortality, underscoring the urgent need to elucidate the molecular mechanisms of HCC and to improve diagnosis and therapeutic approaches. As the most prevalent form of mRNA modification, N6-methyladenosine (m6A) plays a central role in regulating diverse cellular processes in both physiological and pathological conditions, particularly in cancer initiation, development, and progression. This comprehensive review systematically outlines the biological function of three primary classes of m6A regulator proteins, "writers", "erasers", and "readers". It further examines the dysregulated expression patterns of m6A regulators in HCC, analyzes their clinical associations with tumor grade, clinical stage, and survival outcomes, and evaluates their functional contributions to key oncogenic processes, including cell proliferation, apoptosis, and metastasis. Moreover, this review highlights the critical involvement of m6A RNA modification in orchestrating major molecular mechanisms in HCC, offering an in-depth analysis of its regulatory effects on glycolysis, lipid metabolism, ferroptosis, cancer stemness, tumor immunity, cell cycle progression, and resistance to therapy. Finally, the review synthesizes current progress in emerging therapeutic strategies that target the m6A RNA modification for the treatment of HCC. In conclusion, this review presents a systematic summary of recent advances in m6A RNA modification in HCC, delivering valuable insights for future basic and translational studies. Ongoing research into m6A-mediated regulatory mechanisms hold promise for transforming diagnostic paradigms and enabling the development of innovative therapeutic strategies for patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.